A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed/ Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma

Service: Trial Number:
047-12
Principal Investigator: Conducted at:
Miller Children's & Women's Hospital Long Beach
Currently enrolling additional patients:
Yes
Age Range:
all ages

Sorafenib is used to treat cancer (liver and kidney) and is relatively well tolerated with manageable mild to moderate side effects in children and adults. This is a Phase II trial for children and young adults with refractory or recurrent rhabdomyosarcoma, Wilms tumor, HCC, and PTC. Sorafenib will be administered orally approximately every 12 hours continuously for 28-day cycles. A cycle is considered to be 28 days with no rest period between cycles. Subjects may receive up to 24 cycles of therapy in the absence of progressive disease or unacceptable toxicity.

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
Address
,
 
The email to associate with this registration.